Literature DB >> 33982178

Standardization for oncologic head and neck surgery.

Ohad Ronen1, K Thomas Robbins2, Remco de Bree3, Orlando Guntinas-Lichius4, Dana M Hartl5, Akihiro Homma6, Avi Khafif7, Luiz P Kowalski8,9, Fernando López10,11,12, Antti A Mäkitie13, Wai Tong Ng14, Alessandra Rinaldo15, Juan P Rodrigo10,11,12, Alvaro Sanabria16,17, Alfio Ferlito18.   

Abstract

The inherent variability in performing specific surgical procedures for head and neck cancer remains a barrier for accurately assessing treatment outcomes, particularly in clinical trials. While non-surgical modalities for cancer therapeutics have evolved to become far more uniform, there remains the challenge to standardize surgery. The purpose of this review is to identify the barriers in achieving uniformity and to highlight efforts by surgical groups to standardize selected operations and nomenclature. While further improvements in standardization will remain a challenge, we must encourage surgical groups to focus on strategies that provide such a level.

Entities:  

Keywords:  Head and neck cancer; Quality assurance; Standardization; Surgical oncology

Year:  2021        PMID: 33982178     DOI: 10.1007/s00405-021-06867-6

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  43 in total

1.  Defining Quality in Health Care and Measuring Quality in Surgery.

Authors:  Frank Yuan; Kevin C Chung
Journal:  Plast Reconstr Surg       Date:  2016-05       Impact factor: 4.730

Review 2.  Target volume selection and delineation (T and N) for primary radiation treatment of oral cavity, oropharyngeal, hypopharyngeal and laryngeal squamous cell carcinoma.

Authors:  Vincent Grégoire; Cai Grau; Michel Lapeyre; Philippe Maingon
Journal:  Oral Oncol       Date:  2018-11-03       Impact factor: 5.337

3.  How best to measure surgical quality? Comparison of the Agency for Healthcare Research and Quality Patient Safety Indicators (AHRQ-PSI) and the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) postoperative adverse events at a single institution.

Authors:  Robert R Cima; Kandace A Lackore; Sharon A Nehring; Stephen D Cassivi; John H Donohue; Claude Deschamps; Monica Vansuch; James M Naessens
Journal:  Surgery       Date:  2011-08-27       Impact factor: 3.982

Review 4.  Pretreatment body mass index and head and neck cancer outcome: A review of the literature.

Authors:  Dide den Hollander; Ellen Kampman; Carla M L van Herpen
Journal:  Crit Rev Oncol Hematol       Date:  2015-06-18       Impact factor: 6.312

5.  Benchmarking statewide trauma mortality using Agency for Healthcare Research and Quality's patient safety indicators.

Authors:  Darwin Ang; Mark McKenney; Scott Norwood; Stanley Kurek; Brian Kimbrell; Huazhi Liu; Michele Ziglar; James Hurst
Journal:  J Surg Res       Date:  2015-06-03       Impact factor: 2.192

Review 6.  Target definition in prostate, head, and neck.

Authors:  Coen Rasch; Roel Steenbakkers; Marcel van Herk
Journal:  Semin Radiat Oncol       Date:  2005-07       Impact factor: 5.934

7.  Relevance of the Agency for Healthcare Research and Quality Patient Safety Indicators for children's hospitals.

Authors:  Aileen Sedman; J Mitchell Harris; Kristine Schulz; Ellen Schwalenstocker; Denise Remus; Matthew Scanlon; Vinita Bahl
Journal:  Pediatrics       Date:  2004-12-03       Impact factor: 7.124

Review 8.  Quality assurance in head and neck cancer surgery: where are we, and where are we going?

Authors:  Christian Simon; Andreas Dietz; C René Leemans
Journal:  Curr Opin Otolaryngol Head Neck Surg       Date:  2019-04       Impact factor: 2.064

Review 9.  Diagnostic Tumor Markers in Head and Neck Squamous Cell Carcinoma (HNSCC) in the Clinical Setting.

Authors:  Panagiota Economopoulou; Remco de Bree; Ioannis Kotsantis; Amanda Psyrri
Journal:  Front Oncol       Date:  2019-08-29       Impact factor: 6.244

Review 10.  Challenges for Quality Assurance of Target Volume Delineation in Clinical Trials.

Authors:  Amy Tien Yee Chang; Li Tee Tan; Simon Duke; Wai-Tong Ng
Journal:  Front Oncol       Date:  2017-09-25       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.